TAIM
ALNY icon

TD Ameritrade Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

TD Ameritrade Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$1K – 541
2023
Q1 		$1K Buy
+3
New +$631 ﹤0.01% 526

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TD Ameritrade Investment Management's ALNY Position: Q2 2023 in Review

TD Ameritrade Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 3 shares — an estimated $1K sold.

TD Ameritrade Investment Management first reported a position in ALNY in Q1 2023 and held it in 1 quarter. The position peaked at $1K in Q1 2023. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

  • TD Ameritrade Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 3 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $1K.
  • TD Ameritrade Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • TD Ameritrade Investment Management's Alnylam Pharmaceuticals position peaked at $1K in Q1 2023.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.